ATE431740T1 - Kombinationstherapie gegen multiple sklerose - Google Patents
Kombinationstherapie gegen multiple skleroseInfo
- Publication number
- ATE431740T1 ATE431740T1 AT05823965T AT05823965T ATE431740T1 AT E431740 T1 ATE431740 T1 AT E431740T1 AT 05823965 T AT05823965 T AT 05823965T AT 05823965 T AT05823965 T AT 05823965T AT E431740 T1 ATE431740 T1 AT E431740T1
- Authority
- AT
- Austria
- Prior art keywords
- multiple sclerosis
- combination therapy
- cda
- alpha
- agent
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transplanting Machines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63867404P | 2004-12-22 | 2004-12-22 | |
| EP04106910 | 2004-12-22 | ||
| PCT/EP2005/056943 WO2006067134A1 (en) | 2004-12-22 | 2005-12-20 | Combination treatment for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE431740T1 true ATE431740T1 (de) | 2009-06-15 |
Family
ID=35789196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05823965T ATE431740T1 (de) | 2004-12-22 | 2005-12-20 | Kombinationstherapie gegen multiple sklerose |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100129353A1 (enExample) |
| EP (1) | EP1835922B1 (enExample) |
| JP (1) | JP2008524310A (enExample) |
| AT (1) | ATE431740T1 (enExample) |
| AU (1) | AU2005318183B2 (enExample) |
| CA (1) | CA2590471A1 (enExample) |
| CY (1) | CY1109316T1 (enExample) |
| DE (1) | DE602005014570D1 (enExample) |
| DK (1) | DK1835922T3 (enExample) |
| ES (1) | ES2325552T3 (enExample) |
| HR (1) | HRP20090417T1 (enExample) |
| IL (1) | IL183924A (enExample) |
| NO (1) | NO20073635L (enExample) |
| PL (1) | PL1835922T3 (enExample) |
| PT (1) | PT1835922E (enExample) |
| SI (1) | SI1835922T1 (enExample) |
| WO (1) | WO2006067134A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) * | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) * | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) * | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) * | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE408012T1 (de) * | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5208327A (en) * | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69329974T2 (de) * | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| GB9712818D0 (en) * | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| SI1485127T1 (sl) * | 2002-02-25 | 2011-09-30 | Elan Pharm Inc | Dajanje aktivne snovi za zdravljenje vnetja |
| ES2584183T3 (es) * | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
-
2005
- 2005-12-20 HR HR20090417T patent/HRP20090417T1/xx unknown
- 2005-12-20 DK DK05823965T patent/DK1835922T3/da active
- 2005-12-20 EP EP05823965A patent/EP1835922B1/en not_active Expired - Lifetime
- 2005-12-20 AT AT05823965T patent/ATE431740T1/de active
- 2005-12-20 DE DE602005014570T patent/DE602005014570D1/de not_active Expired - Lifetime
- 2005-12-20 JP JP2007547483A patent/JP2008524310A/ja not_active Withdrawn
- 2005-12-20 AU AU2005318183A patent/AU2005318183B2/en not_active Ceased
- 2005-12-20 CA CA002590471A patent/CA2590471A1/en not_active Abandoned
- 2005-12-20 PL PL05823965T patent/PL1835922T3/pl unknown
- 2005-12-20 SI SI200530731T patent/SI1835922T1/sl unknown
- 2005-12-20 WO PCT/EP2005/056943 patent/WO2006067134A1/en not_active Ceased
- 2005-12-20 US US11/722,487 patent/US20100129353A1/en not_active Abandoned
- 2005-12-20 ES ES05823965T patent/ES2325552T3/es not_active Expired - Lifetime
- 2005-12-20 PT PT05823965T patent/PT1835922E/pt unknown
-
2007
- 2007-06-14 IL IL183924A patent/IL183924A/en not_active IP Right Cessation
- 2007-07-13 NO NO20073635A patent/NO20073635L/no not_active Application Discontinuation
-
2009
- 2009-08-12 CY CY20091100869T patent/CY1109316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006067134A1 (en) | 2006-06-29 |
| CY1109316T1 (el) | 2014-07-02 |
| IL183924A0 (en) | 2007-10-31 |
| HRP20090417T1 (hr) | 2009-09-30 |
| DK1835922T3 (da) | 2009-08-03 |
| IL183924A (en) | 2010-11-30 |
| AU2005318183B2 (en) | 2011-03-31 |
| SI1835922T1 (sl) | 2009-10-31 |
| NO20073635L (no) | 2007-09-24 |
| AU2005318183A1 (en) | 2006-06-29 |
| US20100129353A1 (en) | 2010-05-27 |
| PL1835922T3 (pl) | 2009-10-30 |
| CA2590471A1 (en) | 2006-06-29 |
| JP2008524310A (ja) | 2008-07-10 |
| ES2325552T3 (es) | 2009-09-08 |
| DE602005014570D1 (enExample) | 2009-07-02 |
| EP1835922A1 (en) | 2007-09-26 |
| PT1835922E (pt) | 2009-07-08 |
| EP1835922B1 (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
| CO5700791A2 (es) | Metodos para tratar enfermedades relacionadas con interleukin-6 | |
| DE60318192D1 (de) | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| NO20052362L (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| WO2007058990A3 (en) | Therapy using cytokine inhibitors | |
| ATE307625T1 (de) | Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen | |
| DE60036915D1 (de) | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln | |
| DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| TW200616608A (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| NO20064287L (no) | Dalbavancin-materialer for behandling av bakterielle infeksjoner | |
| WO2003049694A3 (en) | Methods of therapy for non-hodgkin's lymphoma | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| JP2006514116A5 (enExample) | ||
| BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
| JP2003528919A5 (enExample) | ||
| CY1113488T1 (el) | Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| BR0317539A (pt) | Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais | |
| NO20073635L (no) | Kombinasjonsbehandling for multippel sklerose | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1835922 Country of ref document: EP |
|
| UEP | Publication of translation of european patent specification |
Ref document number: 1835922 Country of ref document: EP |